A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 3, 2005, Pages 449-456

  Lohmander, L Stefan ^a   McKeith, D ^b   Svensson, O ^c   Malmenas M ^c   Bolin, L ^c   Kalla, A ^d   Genti, G ^e   Szechinski, J ^f   Ramos Remus, C ^e  

^a LUND UNIVERSITY   (Sweden)

^b Castlemilk Health Centre   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e Groote Schuur Hospital ^*  (Mexico)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; IBUPROFEN; NAPROXEN; NITRIC OXIDE DONOR; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM EROSION; DUODENUM ULCER; DYSPEPSIA; EROSION; ESOPHAGUS EROSION; ESOPHAGUS ULCER; FEMALE; FLATULENCE; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPOTENSION; INCIDENCE; INDIGESTION; INFLUENZA; INTESTINE INJURY; KNEE OSTEOARTHRITIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOMES RESEARCH; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; STOMACH EROSION; STOMACH ULCER; SYMPTOM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; NAPROXEN; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PEPTIC ULCER; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 14144252695     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.023572     Document Type: Article

References (40)

1. ACR. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology subcommittee on osteoarthritis guidelines. Arthritis Rheum 2000;43:1905-15.
2. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
3. Laine L. Approaches ID nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
4. Singh G, Triadafilopaulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26:18-24.
5. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989;96:647-55.
6. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-14.
7. Agrawal NM, Caldwell J, Kivitz AJ, Weaver AL, Bocanegra TS, Ball J, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999;21:659-74.
8. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999;282:1921-8.
9. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51:530-7.
10. Hudson N, Taha AS, Russell RI, Trye P, Cottrell J, Mann SG, et al. Famotidine for healing and maintenance in nonsteroidal anti- inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817-22.
11. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
12. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo controlled trial. Arthritis Rheum 2000;43:370-7.
13. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.
14. Hawkey C. NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clin Exp Rheumatol 2001;19:S23-30.
15. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:235-95.
16. Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003;52:600-8.
17. Office of Population Censuses and Surveys. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age in England and Wales, 1993. London: HMSO, 1995.
18. Wallace J. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med 1996;19:346-51.
19. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovosodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-9.
20. Fiorucci S, Antonelli E, Burgaud J, Morelli A. Nitric oxide-releasing NSAIDs. A review of their current status. Drug Saf 2001;24:801-11.
21. Berndt G, Grosser N, Hoogstraate J, Schröder H. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci 2004;21:331-5.
22. Berge O-G, Raud J, Hoogstraate J, Wallace J. The CINOD AZD3582 inhibits cyclooxygenase and reduces pain, inflammation and fever in the rat. Eur J Pharm Sci 2002;17(suppl):S77.
23. Berge O-G, Raud J, Hoogstraate J. AZD3582 reduces pain, inflammation and fever in animals. Ann Rheum Dis 2002;61(suppl 1):286.
24. Davies N, Roseth A, Appleyard C, McKnight W, Del Soldato P, Calignano A, et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects, Aliment Pharmacol Ther 1997;11:69-79.
25. Muscara MN, McKnight W, Del Soldato P, Wallace JL. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 1998;62:PL235-40.
26. Öjteg G, Hällgren A, Hoogstraate J. AZD3582, a COX-inhibiting nitric oxide donator (CINOD), is gastroprotective in the rat. Ann Rhuem Dis 2002;61(suppl 1):288.
27. Hawkey C, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, et al. Gastrointestinal safety of AZD3582: a cyclooxygenase inhibiting nitric oxide donator: proof of concept in humans. Gut 2003;52:1537-42.
28. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13:761-7.
29. Svedlund J, Sjodin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-34.
30. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
31. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
32. Berndt G, Grosser N, Hoogstraate J, Schröder J. A common pathway for nitric oxide release from AZD3582 and glyceryl trinitrate. Ann Rheum Dis 2002;61(suppl 1):269.
33. Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2- selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.
34. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbord RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
35. Vioxx. Rofecoxib tablets and oral suspension. Prescribing information. Whitehouse Station, New Jersey: Merck and Co, 1999.
36. Hawkey CJ, Laine L, Harper SE, Quan HUI, Bolognese JA, Mortensen E, for the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001;15:1593-601.
37. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 1990;35:1494-9.
38. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 1997;32:126-30.
39. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001;96:1998-2004.
40. Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.